questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Cytokines
Monokines
Interleukine-1
Interleukine-1 : Questions médicales fréquentes
Diagnostic
5
Interleukine-1
Tests de laboratoire
Interleukine-1
Maladies auto-immunes
Interleukine-1
Imagerie médicale
Symptômes
5
Interleukine-1
Inflammation
Interleukine-1
Troubles neurologiques
Prévention
5
Interleukine-1
Prévention
Traitements
5
Interleukine-1
Inhibiteurs
Interleukine-1
Anti-inflammatoires
Interleukine-1
Corticostéroïdes
Interleukine-1
Médecine naturelle
Interleukine-1
Thérapie génique
Complications
5
Interleukine-1
Complications
Interleukine-1
Maladies cardiovasculaires
Interleukine-1
Choc septique
Interleukine-1
Troubles neurologiques
Facteurs de risque
5
Interleukine-1
Facteurs de risque
Interleukine-1
Infections
Interleukine-1
Mode de vie
Interleukine-1
Maladies auto-immunes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Interleukine-1 : Questions médicales les plus fréquentes",
"headline": "Interleukine-1 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Interleukine-1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-08-03",
"dateModified": "2026-04-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Interleukine-1"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Monokines",
"url": "https://questionsmedicales.fr/mesh/D015846",
"about": {
"@type": "MedicalCondition",
"name": "Monokines",
"code": {
"@type": "MedicalCode",
"code": "D015846",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.500"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Interleukine-1 alpha",
"alternateName": "Interleukin-1alpha",
"url": "https://questionsmedicales.fr/mesh/D053582",
"about": {
"@type": "MedicalCondition",
"name": "Interleukine-1 alpha",
"code": {
"@type": "MedicalCode",
"code": "D053582",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.500.400.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Interleukine-1 bêta",
"alternateName": "Interleukin-1beta",
"url": "https://questionsmedicales.fr/mesh/D053583",
"about": {
"@type": "MedicalCondition",
"name": "Interleukine-1 bêta",
"code": {
"@type": "MedicalCode",
"code": "D053583",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.500.400.600"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Interleukine-1",
"alternateName": "Interleukin-1",
"code": {
"@type": "MedicalCode",
"code": "D007375",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Antonio Abbate",
"url": "https://questionsmedicales.fr/author/Antonio%20Abbate",
"affiliation": {
"@type": "Organization",
"name": "Division of Cardiology, Department of Internal Medicine, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA."
}
},
{
"@type": "Person",
"name": "Mukundan Attur",
"url": "https://questionsmedicales.fr/author/Mukundan%20Attur",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, New York, USA."
}
},
{
"@type": "Person",
"name": "Hua Zhou",
"url": "https://questionsmedicales.fr/author/Hua%20Zhou",
"affiliation": {
"@type": "Organization",
"name": "Applied Bioinformatics Laboratories, New York University School of Medicine, New York, New York, USA."
}
},
{
"@type": "Person",
"name": "Steven B Abramson",
"url": "https://questionsmedicales.fr/author/Steven%20B%20Abramson",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, New York, USA Stevenb.Abramson@nyumc.org."
}
},
{
"@type": "Person",
"name": "Rod W Hunt",
"url": "https://questionsmedicales.fr/author/Rod%20W%20Hunt",
"affiliation": {
"@type": "Organization",
"name": "The Ritchie Centre, Hudson Institute of Medical Research, Melbourne; Department of Pediatrics, Monash University, Victoria; Monash Newborn, Monash Children's Hospital, Melbourne, Australia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "5-Fluoro/(trifluoromethoxy)-2-indolinone derivatives with anti-interleukin-1 activity.",
"datePublished": "2023-10-10",
"url": "https://questionsmedicales.fr/article/37816092",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ardp.202300217"
}
},
{
"@type": "ScholarlyArticle",
"name": "Apolipoprotein B and interleukin 1 receptor antagonist: reversing the risk of coronary heart disease.",
"datePublished": "2023-10-24",
"url": "https://questionsmedicales.fr/article/37941911",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2023.1278273"
}
},
{
"@type": "ScholarlyArticle",
"name": "Stromal BMP signaling regulates mucin production in the large intestine via interleukin-1/17.",
"datePublished": "2023-10-27",
"url": "https://questionsmedicales.fr/article/37889976",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1126/sciadv.adi1827"
}
},
{
"@type": "ScholarlyArticle",
"name": "\"How to Release or Not Release, That Is the Question.\" A Review of Interleukin-1 Cellular Release Mechanisms in Vascular Inflammation.",
"datePublished": "2024-02-23",
"url": "https://questionsmedicales.fr/article/38390810",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1161/JAHA.123.032987"
}
},
{
"@type": "ScholarlyArticle",
"name": "Serum interleukin-1 is a new biomarker to predict the risk of rebleeding of ruptured intracranial aneurysm after admission.",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37195327",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10143-023-02010-7"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cytokines",
"item": "https://questionsmedicales.fr/mesh/D016207"
},
{
"@type": "ListItem",
"position": 5,
"name": "Monokines",
"item": "https://questionsmedicales.fr/mesh/D015846"
},
{
"@type": "ListItem",
"position": 6,
"name": "Interleukine-1",
"item": "https://questionsmedicales.fr/mesh/D007375"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Interleukine-1 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Interleukine-1",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Interleukine-1",
"description": "Comment diagnostiquer une surproduction d'IL-1 ?\nQuels tests sont utilisés pour évaluer l'IL-1 ?\nL'IL-1 est-elle mesurée dans des maladies spécifiques ?\nQuels symptômes peuvent indiquer un excès d'IL-1 ?\nL'imagerie peut-elle aider à diagnostiquer des troubles liés à l'IL-1 ?",
"url": "https://questionsmedicales.fr/mesh/D007375#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Interleukine-1",
"description": "Quels sont les symptômes d'une inflammation due à l'IL-1 ?\nL'IL-1 peut-elle provoquer de la fièvre ?\nQuels autres symptômes sont associés à l'IL-1 ?\nL'IL-1 est-elle liée à des douleurs articulaires ?\nPeut-on observer des symptômes neurologiques liés à l'IL-1 ?",
"url": "https://questionsmedicales.fr/mesh/D007375#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Interleukine-1",
"description": "Peut-on prévenir les maladies liées à l'IL-1 ?\nLes vaccinations influencent-elles l'IL-1 ?\nLe stress affecte-t-il les niveaux d'IL-1 ?\nL'exercice physique aide-t-il à réguler l'IL-1 ?\nLes habitudes alimentaires influencent-elles l'IL-1 ?",
"url": "https://questionsmedicales.fr/mesh/D007375#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Interleukine-1",
"description": "Quels traitements ciblent l'IL-1 ?\nL'IL-1 peut-elle être traitée par des anti-inflammatoires ?\nLes corticostéroïdes affectent-ils l'IL-1 ?\nY a-t-il des traitements naturels pour l'IL-1 ?\nComment la thérapie génique pourrait-elle cibler l'IL-1 ?",
"url": "https://questionsmedicales.fr/mesh/D007375#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Interleukine-1",
"description": "Quelles complications peuvent survenir avec l'IL-1 ?\nL'IL-1 est-elle liée à des maladies cardiovasculaires ?\nPeut-on développer un choc septique à cause de l'IL-1 ?\nL'IL-1 est-elle impliquée dans le diabète ?\nDes troubles neurologiques peuvent-ils être causés par l'IL-1 ?",
"url": "https://questionsmedicales.fr/mesh/D007375#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Interleukine-1",
"description": "Quels facteurs augmentent le risque d'IL-1 élevé ?\nL'âge influence-t-il les niveaux d'IL-1 ?\nLes infections peuvent-elles augmenter l'IL-1 ?\nLe mode de vie sédentaire affecte-t-il l'IL-1 ?\nLes maladies auto-immunes sont-elles un facteur de risque pour l'IL-1 ?",
"url": "https://questionsmedicales.fr/mesh/D007375#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une surproduction d'IL-1 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux d'IL-1 peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'IL-1 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les dosages ELISA et les tests de cytométrie en flux sont courants."
}
},
{
"@type": "Question",
"name": "L'IL-1 est-elle mesurée dans des maladies spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est souvent mesurée dans les maladies auto-immunes et inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un excès d'IL-1 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, douleurs articulaires et fatigue peuvent signaler une surproduction."
}
},
{
"@type": "Question",
"name": "L'imagerie peut-elle aider à diagnostiquer des troubles liés à l'IL-1 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut montrer des signes d'inflammation, mais ne mesure pas l'IL-1."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une inflammation due à l'IL-1 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rougeur, chaleur, gonflement et douleur au site d'inflammation sont fréquents."
}
},
{
"@type": "Question",
"name": "L'IL-1 peut-elle provoquer de la fièvre ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-1 est un pyrogène et peut induire de la fièvre."
}
},
{
"@type": "Question",
"name": "Quels autres symptômes sont associés à l'IL-1 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, perte d'appétit et malaise général peuvent également se manifester."
}
},
{
"@type": "Question",
"name": "L'IL-1 est-elle liée à des douleurs articulaires ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-1 joue un rôle dans l'arthrite et peut causer des douleurs articulaires."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes neurologiques liés à l'IL-1 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes neurologiques comme des troubles de la mémoire peuvent survenir."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées à l'IL-1 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et un mode de vie actif peuvent réduire le risque."
}
},
{
"@type": "Question",
"name": "Les vaccinations influencent-elles l'IL-1 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines vaccinations peuvent moduler la réponse de l'IL-1."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il les niveaux d'IL-1 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut augmenter la production d'IL-1."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à réguler l'IL-1 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut réduire l'inflammation et les niveaux d'IL-1."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles l'IL-1 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut aider à moduler l'IL-1."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent l'IL-1 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inhibiteurs de l'IL-1, comme l'anakinra, sont utilisés pour traiter certaines maladies."
}
},
{
"@type": "Question",
"name": "L'IL-1 peut-elle être traitée par des anti-inflammatoires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les anti-inflammatoires non stéroïdiens (AINS) peuvent réduire ses effets."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes affectent-ils l'IL-1 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent diminuer la production d'IL-1 et l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour l'IL-1 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes anti-inflammatoires peuvent aider à moduler l'IL-1."
}
},
{
"@type": "Question",
"name": "Comment la thérapie génique pourrait-elle cibler l'IL-1 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique pourrait potentiellement réguler l'expression de l'IL-1."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'IL-1 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maladies auto-immunes, des infections et des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "L'IL-1 est-elle liée à des maladies cardiovasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-1 est impliquée dans l'inflammation qui peut conduire à des maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Peut-on développer un choc septique à cause de l'IL-1 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surproduction d'IL-1 peut contribuer au choc septique en cas d'infection."
}
},
{
"@type": "Question",
"name": "L'IL-1 est-elle impliquée dans le diabète ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-1 joue un rôle dans l'inflammation associée au diabète de type 2."
}
},
{
"@type": "Question",
"name": "Des troubles neurologiques peuvent-ils être causés par l'IL-1 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-1 est impliquée dans des troubles neurologiques comme la maladie d'Alzheimer."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'IL-1 élevé ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, le tabagisme et le stress chronique sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux d'IL-1 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux d'IL-1 peuvent augmenter avec l'âge, surtout en cas d'inflammation."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles augmenter l'IL-1 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections aiguës peuvent stimuler la production d'IL-1."
}
},
{
"@type": "Question",
"name": "Le mode de vie sédentaire affecte-t-il l'IL-1 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire peut augmenter les niveaux d'IL-1 et l'inflammation."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque pour l'IL-1 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies auto-immunes peuvent entraîner une surproduction d'IL-1."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 25/04/2026
Contenu vérifié selon les dernières recommandations médicales
6 publications dans cette catégorie
Affiliations :
Division of Cardiology, Department of Internal Medicine, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
2 publications dans cette catégorie
Affiliations :
Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, New York, USA.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
Applied Bioinformatics Laboratories, New York University School of Medicine, New York, New York, USA.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, New York, USA Stevenb.Abramson@nyumc.org.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
The Ritchie Centre, Hudson Institute of Medical Research, Melbourne; Department of Pediatrics, Monash University, Victoria; Monash Newborn, Monash Children's Hospital, Melbourne, Australia.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
The Ritchie Centre, Hudson Institute of Medical Research, Melbourne; Department of Pediatrics, Monash University, Victoria, Australia.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
The Ritchie Centre, Hudson Institute of Medical Research, Melbourne; Department of Pediatrics, Monash University, Victoria; Monash Newborn, Monash Children's Hospital, Melbourne, Australia.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
The Ritchie Centre, Hudson Institute of Medical Research, Melbourne; Department of Obstetrics and Gynaecology, Monash University, Victoria, Australia.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopedics, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, China. Electronic address: 13776698080@139.com.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China (mainland).
Publications dans "Interleukine-1" :
Expression and Mechanism of Interleukin 1 (IL-1), Interleukin 2 (IL-2), Interleukin 8 (IL-8), BMP, Fibroblast Growth Factor 1 (FGF1), and Insulin-Like Growth Factor (IGF-1) in Lumbar Disc Herniation.
Medical science monitor : international medical journal of experimental and clinical research
2019-02-04
Retracted: Expression and Mechanism of Interleukin 1 (IL-1), Interleukin 2 (IL-2), Interleukin 8 (IL-8), BMP, Fibroblast Growth Factor 1 (FGF1), and Insulin-Like Growth Factor (IGF-1) in Lumbar Disc Herniation.
Medical science monitor : international medical journal of experimental and clinical research
2022-10-21
2 publications dans cette catégorie
Affiliations :
Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China (mainland).
Publications dans "Interleukine-1" :
Expression and Mechanism of Interleukin 1 (IL-1), Interleukin 2 (IL-2), Interleukin 8 (IL-8), BMP, Fibroblast Growth Factor 1 (FGF1), and Insulin-Like Growth Factor (IGF-1) in Lumbar Disc Herniation.
Medical science monitor : international medical journal of experimental and clinical research
2019-02-04
Retracted: Expression and Mechanism of Interleukin 1 (IL-1), Interleukin 2 (IL-2), Interleukin 8 (IL-8), BMP, Fibroblast Growth Factor 1 (FGF1), and Insulin-Like Growth Factor (IGF-1) in Lumbar Disc Herniation.
Medical science monitor : international medical journal of experimental and clinical research
2022-10-21
2 publications dans cette catégorie
Affiliations :
Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China (mainland).
Publications dans "Interleukine-1" :
Expression and Mechanism of Interleukin 1 (IL-1), Interleukin 2 (IL-2), Interleukin 8 (IL-8), BMP, Fibroblast Growth Factor 1 (FGF1), and Insulin-Like Growth Factor (IGF-1) in Lumbar Disc Herniation.
Medical science monitor : international medical journal of experimental and clinical research
2019-02-04
Retracted: Expression and Mechanism of Interleukin 1 (IL-1), Interleukin 2 (IL-2), Interleukin 8 (IL-8), BMP, Fibroblast Growth Factor 1 (FGF1), and Insulin-Like Growth Factor (IGF-1) in Lumbar Disc Herniation.
Medical science monitor : international medical journal of experimental and clinical research
2022-10-21
2 publications dans cette catégorie
Affiliations :
Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. kleina@ccf.org.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
Humanitas Research Hospital-IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy; Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy. Electronic address: cecilia.garlanda@humanitasresearch.it.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
Humanitas Research Hospital-IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy; Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy; The William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: alberto.mantovani@humanitasresearch.it.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Publications dans "Interleukine-1" :
2 publications dans cette catégorie
Affiliations :
The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Publications dans "Interleukine-1" :
The pro-inflammatory cytokine interleukin-1 (IL-1) drives the pathogenesis of several inflammatory diseases. Recent studies have revealed that 2-indolinones can modulate cytokine responses. Therefore,...
Epidemiological evidence for the link of interleukin 1 (IL-1) and its inhibition with cardiovascular diseases (CVDs) remains controversial. We aim to investigate the cardiovascular effects of IL-1 rec...
Genetic variants identified from a genome-wide association study involving 30,931 individuals were used as instrumental variables for the serum IL-1Ra concentrations. Genetic associations with CVDs an...
Genetically determined IL-1Ra level was associated with increased risk of coronary heart disease (CHD; OR, 1.07; 95% CI: 1.03-1.17) and myocardial infarction (OR, 1.13; 95% CI: 1.04-1.21). The main re...
Apolipoprotein B represents the key driver, and a potential target for reversal of the causal link between serum IL-1Ra and increased risk of CHD/MI. The combined therapy involving IL-1 inhibition and...
Bone morphogenic protein (BMP) signaling is critical for intestinal development, homeostasis, and function performance. Although the function of BMP signaling in the intestinal epithelium is well appr...
Cardiovascular disease remains the leading cause of death worldwide, characterized by atherosclerotic activity within large and medium-sized arteries. Inflammation has been shown to be a primary drive...
Interleukin-1 (IL-1) could induce inflammation of the aneurysm wall, which might be related to intracranial aneurysm rupture. The aim of this study was to investigate whether IL-1 could serve as a bio...
Colchicine is the mainstay of familial Mediterranean fever treatment and interleukin (IL-1) antagonists are the treatment of choice in resistant patients. We aimed to investigate efficacy of IL-1 anta...
A total of 111 patients fulfilling Euro fever and Tel-Hashomer criteria and treated with IL-1 antagonists were included in the study. Patients were grouped according to their recent damage status: no ...
Forty-six patients (43,2 %) had damage according to the mADDI. Damage was commonly observed at musculoskeletal, renal and reproductive domains. Median duration of treatment was forty-five months. Two ...
We evaluated change in damage accrual while using IL-1 antagonists in patients with FMF. Physicians should pay attention to controlling inflammation to prevent further damage, especially in those with...
This study aimed to evaluate the association of SNPs of the IL-1 family with the clinical severity of knee OA. This case‒control study was performed among 100 healthy knees and 130 osteoarthritis (OA)...
Cryopyrin-associated periodic syndromes (CAPS) are orphan hereditary auto-inflammatory diseases with various phenotypes, including chronic kidney disease (CKD). Current therapies inhibit interleukin-1...
Recombinant human interleukin-1 receptor antagonist (anakinra) is an anti-inflammatory with efficacy in animal models of stroke. We tested the effect of anakinra on perihaematomal oedema in acute intr...
We conducted a multicentre, randomised, double-blind, placebo-controlled trial in patients with acute, spontaneous, supratentorial ICH between May 2019 and February 2021. Patients were randomised to 1...
25 patients (target = 80) were recruited, 14 randomised to anakinra, 11 to placebo. Mean age was 67 and 52% were male. The anakinra group had higher median baseline ICH volume (12.6 ml, interquartile ...
We describe feasibility for delivering anakinra in acute ICH and provide preliminary safety data. We lacked power to test for effects on oedema thus further trials will be required....
Activated fibroblast-like synoviocytes (FLS) are drivers of synovitis and structural joint damage in rheumatoid arthritis (RA). Despite the use of disease-modifying drugs, only about 50% of RA patient...
Primary RA-FLS were activated by stimulation with interleukin-1β (IL-1β) or platelet-derived growth factor + IL-1β in the presence or absence of MTX or TOFA, with or without additional inhibitors. Co-...
Six thousand three hundred fifty genes were differentially expressed, the majority being upregulated, in MTX-treated activated RA-FLS and 970 genes, the majority being downregulated, in TOFA-treated s...
MTX treatment induces secretion of IL-1 from activated RA-FLS which by autocrine signaling augments their release of GM-CSF. This unexpected effect of MTX might contribute to the persistence of synovi...